The expansion places ACROBiosystems directly among hospitals, translational research institutes, and biotech firms within the Campus Grand Parc. Having joined the Paris-Saclay Cancer Cluster in 2025, the company aims to move beyond remote support, utilizing its new office to facilitate daily interactions with clinical partners. The HIVE, operated by Kadans Science Partner, serves as the physical bridge for this integration.
ACROBiosystems Establishes French Hub at The HIVE Innovation Center
ACROBiosystems is anchoring its French operations within The HIVE Innovation Center at Villejuif’s Campus Grand Parc, a strategic move intended to integrate the global biotechnology firm into the heart of the Paris-Saclay cancer research ecosystem and accelerate collaboration on next-generation oncology therapies.
Mike Chen, Chairman and CEO of ACROBiosystems, noted that the Paris-Saclay region represents a critical convergence of research and clinical excellence. For the company, which employs nearly 1,000 people globally and provides a range of products from recombinant proteins to GMP-grade services, the site offers proximity to the teams developing advanced immunotherapeutics. Sandrine Lo, Investment & Asset Manager at Kadans Science Partner, described the arrival as a validation of the campus’s international appeal, marking a shift toward more localized, collaborative research support for European drug developers.
Comments (0)
No comments yet. Be the first!